What Matinas BioPharma Holdings, Inc. does

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Bedminster, New Jersey. The company developed a proprietary Lipid Nano-Crystal (LNC) drug delivery platform designed to enable safe, intracellular, oral delivery of small molecules, oligonucleotides, vaccines, peptides, and proteins — a delivery modality intended to reduce toxicity and improve bioavailability compared to IV-only formulations. Its lead clinical asset MAT2203 is an oral formulation of amphotericin B for invasive fungal infections including cryptococcal meningitis, which received QIDP, Orphan Drug, and Fast Track FDA designations based on positive Phase 2 EnACT study data. The pipeline also included MAT2501 (oral amikacin for nontuberculous mycobacterial lung disease, supported by the Cystic Fibrosis Foundation) and MAT9001/LYPDISO (a prescription omega-3 composition that showed superiority versus Vascepa in head-to-head clinical trials). The company pursued research collaborations with NIH/NINDS and NIAID, and held strategic platform evaluation agreements with undisclosed top-tier pharmaceutical companies for oligonucleotide delivery.

The company has never generated product revenue and has reported losses in five consecutive fiscal years through December 31, 2025. Its commercial model was oriented toward licensing the LNC platform to larger pharmaceutical partners and obtaining FDA approval for its own drug candidates. In October 2024, the company terminated MAT2203 partnership negotiations and implemented an 80% workforce reduction; by January 2025, cash had declined to $10.295M and the CFO had resigned. In April 2026, NYSE American issued a non-compliance notice due to stockholders' equity of $3.02M falling below required thresholds.

In July 2026, the company executed two concurrent transactions signaling a strategic wind-down of its pharmaceutical operations: a definitive Business Combination Agreement with GH Power Inc. to form NYSE-listed GHP International (a clean energy company) in which Matinas equityholders will retain only ~9% of the combined entity, and a stock purchase agreement to sell its Matinas BioPharma Nanotechnologies subsidiary — including the LNC platform and MAT2203 — to Azurity Pharmaceuticals for $4.0M upfront plus up to $17.5M in milestones and royalties.

Name

Matinas BioPharma Holdings, Inc.

Legal name

Matinas BioPharma Holdings, Inc.

Website

http://matinasbiopharma.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Matinas BioPharma Holdings (NYSE American: MTNB) is a pre-revenue clinical-stage biopharmaceutical company that developed a lipid nano-crystal (LNC) drug delivery platform with candidates MAT2203 (oral amphotericin B), MAT2501, and MAT9001. The company is undergoing wind-down via merger with GH Power.

Ownership category

akta.pro rank

Headquarters

HQ city

Bedminster

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Product Development and Commercialization: Pre-revenue clinical-stage company developing pharmaceutical products. Revenue expected upon FDA approval and commercialization of MAT2203, MAT9001, and MAT2501. Concurrently selling LNC drug delivery technology subsidiary to Azurity Pharmaceuticals for $4.0M upfront plus up to $17.5M in milestones.
2. Strategic Partnerships and Licensing: Company pursues research collaborations and licensing agreements with larger pharmaceutical companies for its LNC platform technology. Currently in discussions with multiple strategic and research partners.
3. Merger with GH Power: Business combination with GH Power to create publicly traded clean energy company GHP International. GH Power equityholders will own ~91% and Matinas equityholders ~9% of combined entity.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Matinas BioPharma is a clinical-stage biopharmaceutical company developing therapeutics built on its proprietary Lipid Nano-Crystal (LNC) drug delivery platform. The platform enables safe, intracellular, oral delivery of small molecules and oligonucleotides, and is the foundation for its pipeline including MAT2203 (oral amphotericin B for invasive fungal infections), MAT2501 (oral amikacin for NTM lung disease), and MAT9001/LYPDISO (prescription omega-3 for cardiovascular and metabolic conditions).

Product overview

Matinas BioPharma is a clinical-stage biopharmaceutical company with a portfolio built around its proprietary Lipid Nano-Crystal (LNC) drug delivery platform. The LNC platform enables intracellular oral delivery of therapeutics including small molecules and oligonucleotides. The company's product pipeline includes: MAT2203 (oral amphotericin B for invasive fungal infections), MAT2501 (oral amikacin for NTM lung disease), and MAT9001/LYPDISO (omega-3 fatty acid composition for cardiovascular conditions). All product candidates are in clinical development stages and not yet commercially available.

Differentiator

Problem solved

Functional benefit

Brands

• LNC Platform: Lipid Nano-Crystal platform delivery technology for intracellular delivery of therapeutics
• MAT2203
• MAT9001

Products and services

• LNC Platform Proprietary lipid nano-crystal drug delivery platform technology that enables safe, intracellular, oral delivery of small molecules and small oligonucleotides, potentially making drugs safer, more tolerable, less toxic, and orally bioavailable.
• MAT2203 Oral LNC formulation of amphotericin B, a broad-spectrum antifungal agent, developed for the treatment of invasive fungal infections. Successfully evaluated in Phase 2 EnACT study in HIV patients with cryptococcal meningitis. Has received QIDP, Orphan Drug, and Fast Track FDA designations.
• MAT2501 Oral LNC formulation of the broad-spectrum aminoglycoside antibiotic amikacin, under development primarily for treating nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis. Supported by funding from the Cystic Fibrosis Foundation.
• MAT9001 (LYPDISO) Prescription-only omega-3 fatty acid-based composition comprising EPA, DPA, and other omega-3 fatty acids, under development for severe hypertriglyceridemia and cardiovascular/metabolic conditions. FDA conditionally accepted LYPDISO as the brand name. Demonstrated superiority versus Vascepa in head-to-head clinical trials, including approximately 6-fold higher EPA bioavailability.

Quantifiable outcome

• Phase 2 EnACT study met primary endpoint with robust survival in HIV patients with cryptococcal meningitis
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered minor and core.

• TKMS (ThyssenKrupp Marine Systems)minorStrategic or Co-development Partner · 30 July 2026Through GH Power partnership: GH Power and TKMS exploring integration of modular clean energy technology into future defense and maritime manufacturing applications in Canada under non-binding memorandum of understanding.
• Azurity PharmaceuticalscoreStrategic or Co-development Partner · 13 July 2026Stock purchase agreement for Azurity Pharmaceuticals to acquire Matinas BioPharma Nanotechnologies, including LNC drug delivery technology platform and lead product candidate MAT2203, for $4.0 million upfront plus up to $17.5 million in potential milestone payments and royalties.
• GH Power Inc.coreStrategic or Co-development Partner · 13 July 2026Definitive Business Combination Agreement creating new NYSE-listed public company GHP International. GH Power equityholders will own approximately 91% and Matinas equityholders approximately 9% of combined entity. Transaction expected to close Q4 2026 with $15 million minimum PIPE financing.
• National Institute of Allergy and Infectious Diseases (NIAID)coreStrategic or Co-development Partner · 7 December 2020Collaboration to evaluate oral formulations of Gilead's antiviral remdesivir utilizing Matinas' LNC platform delivery technology for potential COVID-19 treatment applications.
• Undisclosed Top Global Pharmaceutical CompanycoreStrategic or Co-development Partner · 10 January 2019Research evaluation agreement to formulate select oligonucleotides using proprietary LNC platform delivery technology. Promising formulations tested in in vitro and in vivo preclinical studies. Terms confidential for competitive reasons.
• National Institute of Neurological Disorders and Stroke (NINDS) / NIHcoreStrategic or Co-development Partner · 9 July 2018Research collaboration focused on development of novel HIV therapy combining targeted antisense oligonucleotides (ASO) with Matinas' LNC delivery technology. Goal is to inhibit Tat/viral mRNA translation. Studies conducted at NIH in Bethesda, MD under direction of Dr. Avindra Nath.

Scale indicators11 records

Recent moves8 records

Expansion highlights5 records

Market position

Weaknesses5 records

Competitive moat3 records

Customer concentration

• Xtwitter.com/MatinasBio
• Facebookfacebook.com/matinasbiopharma
• LinkedInlinkedin.com/company/matinas-biopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Matinas BioPharma Holdings, Inc.